ArticleAmerican journal of cancer research2023

Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway.

Guodong Huang et al.PubMed ↗Full text ↗

No numbers read from the abstract.